The Phase 3 HAELO data presentation at EAACI is the key catalyst. Positive efficacy/safety data could drive significant upside; negative results would be bearish. Monitor for abstract release and investor reaction post-presentation.
Price Chart
Executive Summary
Intellia Therapeutics announced that Phase 3 HAELO trial data for lonvo-z (NTLA-2002) in hereditary angioedema will be presented at EAACI 2026. The filing is a pipeline update with no financial results or guidance; the EPS miss of -$0.81 vs -$0.80 consensus is negligible for a pre-revenue biotech.
Key Financial Metrics
Key Facts
- Phase 3 HAELO data for lonvo-z (NTLA-2002) in HAE to be presented at EAACI June 12-15, 2026
- Lonvo-z has FDA RMAT, Orphan Drug, and EMA PRIME designations
- EPS of -$0.81 vs consensus -$0.80 (1.8% miss) — immaterial for pre-revenue stage
- No revenue or guidance reported; company is pre-commercial
Financial Impact
No financial impact; EPS miss of $0.01 is negligible for a pre-revenue biotech
Risk Factors
- Phase 3 data may fail to meet efficacy or safety endpoints
- Regulatory approval timeline uncertain; competition from existing HAE therapies
- Pre-revenue company with high cash burn; dilution risk if financing needed
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3304241 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 2, 2026 23d ago | Press Release | $12.75 $12.58 | ▼ −1.33% | ▼ −1.76% | $11.23 (−11.92%) |
Sep 8, 2026 6w ago | 8-K | $12.21 $11.60 | ▼ −5.00% | ▼ −4.66% | $11.23 (−8.03%) |
Aug 6, 2026 11w ago | 8-K | $11.24 $11.83 | ▲ +5.25% | ▲ +4.04% | $11.23 (−0.09%) |
Jun 15, 2026 19w ago | 8-K | $14.92 $15.75 | ▲ +5.56% | ▲ +6.95% | $11.23 (−24.73%) |
Jun 13, 2026 19w ago | Press Release | $14.92 $15.75 | ▲ +5.56% | ▲ +6.95% | $11.23 (−24.73%) |
Jun 1, 2026 21w ago | Press Release | $13.73 $13.54 | ▼ −1.38% | ▲ +1.37% | $11.23 (−18.21%) |
May 11, 2026 24w ago | 8-K | $14.42 $12.69 | ▼ −12.00% | ▼ −11.91% | $11.23 (−22.12%) |
Apr 27, 2026 25w ago | Press Release | $13.20 $13.87 | ▼ −5.08% | ▼ −3.38% | $11.23 (+14.92%) |
Apr 27, 2026 26w ago | 8-K | $13.04 $13.87 | ▲ +6.37% | ▲ +5.96% | $11.23 (−13.88%) |
Apr 3, 2026 29w ago | Press Release | $13.30 $14.26 | ▲ +7.22% | ▲ +3.08% | $11.23 (−15.56%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers